REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP issued a solicitation notice reminding Regeneron Pharmaceuticals investors of a class action lawsuit alleging securities fraud. The complaint alleges the company made false statements regarding the Phase III Fianlimab-Libtayo Study, claiming success was likely based on flawed statistical assumptions and a failure to demonstrate clinical differentiation.
Key figures
- Class period end
- May 15, 2026
- Class period start
- August 1, 2025
- Lead plaintiff deadline
- September 14, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.